Skip to main content

Merck expands in Asia and proposes to acquire Australia’s Viralytics

Leading science and technology company Merck (known as MilliporeSigma in the US) has announced agreements in China, India and South Korea that will see the company invest €40 million in the region.

The company has signed an agreement with Incheon Free Economic Zone (IFEZ) to build an integrated cell culture facility in Songdo, Incheon. Located on 10,141m2 of land, the new centre will include cell culture media facilities and a logistics infrastructure. Construction is expected to begin in May 2018 and to be completed by mid-2019.

Will Brexit affect access to medicines?

Chris Gould, managing director at Active Pharma Ideas Ltd, examines the “Brexit balancing act” between patient access to medicines, industry’s concerns and the complexities facing those negotiating.

Riding high on the winds of change: India

The Indian chemicals industry, with a market size of US$145 billion is the seventh largest producer of chemicals worldwide and the third largest producer in Asia after China and Japan. According to the Chemical Industry Achievement report 2016, the market is expected to reach US$70 billion by 2020.

Doing it in stages

Martin Wuensche and Don Nelson of Albemarle examine the benefits of staging the implementation of a manufacturing intelligence system
Subscribe to Pharmaceuticals

 

 

 

AMRI banner advert